Pharmaceuticals, Medical Devices
American multinational pharmaceutical + medtech company (NYSE: JNJ). Operates Janssen Pharmaceuticals, MedTech (surgical, vision, orthopedics). $85bn revenue 2023. 130,000+ employees. J&J Thailand manages innovative-medicines + consumer + medtech portfolio.
Composite score across 5 categories MNCs operating in Thailand can demonstrate.
How this is computed: a weighted average of 5 sub-scores. Higher weight on signals an MNC has agency over (Thailand venue depth, international disclosure framework adoption, DEI policy explicitness) and lower weight on audit / scale signals that depend on company size.
How Johnson & Johnsonis showing up for Thailand's LGBTQ+ community
Inclusion Dividend
Not yet enrolled
Creator partners
0
verified Thai KOLs
Audit history
Last 2023
Thailand presence
Single market presence
PrideShow LGBTQ+ ESG score (global) — Thailand-specific signals are above
86
Platinum · A+
LGBTQ+ Policy
100
Supply Chain
75
Community
70
Reporting
100
HRC Corporate Equality Index 100% score (20+ consecutive years)
Stonewall Top 100 Employers UK
Open&Out — J&J global LGBTQ+ ERG with 15,000+ members
2023 Health for Humanity Report — GRI / TCFD / CDP / SASB aligned
CDP Climate A-List
DJSI World + FTSE4Good + Bloomberg Gender-Equality Index
Johnson & Johnson Foundation — $50M+ annual community giving
Signatory to UN Global Compact + SBTi
Our Race to Health Equity — $800M commitment to US health equity
Transgender-inclusive benefits in 70+ countries
Access Accelerated — emerging-market NCD programme
Reach Johnson & Johnson's Thailand and APAC teams through PrideShow. Whether you're an NGO with a partnership idea, an SME on the supplier path, or a fellow MNC exploring co-activation — start the conversation here.
Is this your company?
Claim the listing to manage your Thailand inclusion evidence, respond to inbound enquiries, and connect with NGO and creator partners. Or sponsor PrideShow 2026 directly.
